Conferences and Events > Forthcoming Conferences and Events >

BHIVA webinar - ANCHOR Study: results and their implications

Date and Time: Wednesday 28th September 2022, 16:30 – 18:00


People with HIV are at higher risk of HPV-related conditions, including anal cancer. CROI 2022 saw the presentation of the Anal Cancer HSIL Outcomes Research (ANCHOR) Study which compared active monitoring with treatment for people with pre-cancerous lesions detected at anoscopy. Treatment led to an almost 60% reduction in anal cancer incidence and the trial was stopped early.

However, many questions remain including the feasibility, cost-effectiveness and longer-term benefit of this strategy, not to mention the impact of HPV vaccination. This special BHIVA session brings together experts in the field to summarise the ANCHOR findings, review ongoing trials in this area and discuss the implications for research and care.


Click here to register. Registration is free of charge.


Simon Collins, HIV i-Base
Tristan Barber, Royal Free London NHS Trust

The ANCHOR Study
Iain Reeves, Homerton University Hospital, London

Perspective of HPV in women
Deirdre Lyons, Imperial College Healthcare NHS Trust

Management of screening and treatment of anal pre-cancer/cancer in people with HIV
Tamzin Cuming, Homerton University Hospital, London

Richard Gilson, Chief Investigator, SEPAC study, University College London

Panel Discussion